{"disease":{"id":"msi-h-dmmr-gastric-cancer","name":"msi h dmmr gastric cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06250036","title":"Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}